While traditional antibodies are limited to cell-surface antigens, our next-generation TCR-mimic (TCRm) antibody platform enables targeting of the vast intracellular proteome, allowing us to address tumor-specific targets such as cancer-testis antigens. This presentation will detail the engineering strategies used to build the next generation of TCRm T cell engagers, designed to achieve a greater therapeutic window in targeting HLA-peptide complexes, and share recent data on how to overcome challenges in treatment of solid tumors.

Our mission is to transform cancer care by activating the immune system to deliver durable clinical benefit with minimal treatment burden. Aglatimagene besadenovec is a multimodal immunotherapy designed to induce immunogenic tumour cell death and stimulate systemic anti-tumour immunity. This presentation will highlight its mechanism of action, combining localized viral-mediated cytotoxicity with prodrug activation and immune priming. Clinical and immunological data across solid tumours demonstrates aglatimagene’s therapeutic potential.

Humoral immunity is increasingly recognised as a key determinant of outcome in melanoma. This talk will focus on distinct circulating and intratumoural B cell signatures and antibody isotype profiles we found to be be linked with response and toxicity associated with immune checkpoint inhibitor immunotherapy. Humoral immune signatures conditioned in tumour environments, reveal novel biomarkers for predicting and monitoring immunotherapy efficacy.